Publications

Cancer gene therapy is based on the transfer of genetic material to cancer cells to modify a normal or abnormal cellular function, or to induce cell death. Modified viruses or stem cells have been used as carriers to transfer the genetic material to cancer cells avoiding trafficking through normal cells. However, although the current vectors have been successful in delivering genes in vitro and in vivo, little has been achieved with human cerebral gliomas. Poor transduction efficiency of viruses in human glioma cells and limited spread and distribution to the tumor limits our current expectations for successful gene therapy of central nervous system cancer until and if effective transfer vehicles are available. Nevertheless, continuing research in better vector development may overcome these limitations and offer a therapeutic advantage over the standard therapies for glioma.

Posted on September 18th, 2009 | Read more

Gendicine® (recombinant human p53 adenovirus injection) is an innovative gene therapy drug developed by SiBiono GeneTech Co., Ltd (SiBiono), which owns its full intellectual property. In October 2004, SiBiono successfully obtained the New Drug License, Manufacturing Approval and GMP Certificate from the State Food & Drug Administration of China, becoming the world’s first authority approved gene therapy drug producer. Gendicine provides a novel, safe and effective therapy to fight against tumors. Gendicine is genetically engineered adenovirus, comprising of two functional components: human wild-type p53 tumor suppressor gene and recombinant serotype 5 adenoviral vector. The adenoviral vector acts as the delivery vehicle to carry p53 gene into tumor cells to initiate their apoptosis…

Posted on September 7th, 2009 | Read more

An exclusive interview with Dr. Zhaohui Peng, founder and CEO of Shenzhen SiBiono GeneTech, who has made history by becoming the first Biotech Company approved to market its gene therapy medication ‘Gendicine’. In October 2003, ‘Gendicine’ was approved by the SFDA for treatment of head and neck squamous cell carcinoma (HNSCC), becoming the first gene therapy available to patients.

Posted on September 7th, 2009 | Read more